PREVACID IV Drug Patent Profile
✉ Email this page to a colleague
When do Prevacid Iv patents expire, and when can generic versions of Prevacid Iv launch?
Prevacid Iv is a drug marketed by Takeda Pharms Na and is included in one NDA.
The generic ingredient in PREVACID IV is lansoprazole. There is one drug master file entry for this compound. Sixty-two suppliers are listed for this compound. Additional details are available on the lansoprazole profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Prevacid Iv
A generic version of PREVACID IV was approved as lansoprazole by MYLAN PHARMS INC on November 10th, 2009.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for PREVACID IV?
- What are the global sales for PREVACID IV?
- What is Average Wholesale Price for PREVACID IV?
Summary for PREVACID IV
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 137 |
| Clinical Trials: | 42 |
| Patent Applications: | 4,608 |
| DailyMed Link: | PREVACID IV at DailyMed |
Recent Clinical Trials for PREVACID IV
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Janssen Research & Development, LLC | Phase 1 |
| McGill University Health Centre/Research Institute of the McGill University Health Centre | Phase 4 |
| McGill University Health Center | Phase 4 |
US Patents and Regulatory Information for PREVACID IV
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Takeda Pharms Na | PREVACID IV | lansoprazole | INJECTABLE;INTRAVENOUS | 021566-001 | May 27, 2004 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for PREVACID IV
See the table below for patents covering PREVACID IV around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Austria | 42554 | ⤷ Start Trial | |
| Australia | 4589585 | ⤷ Start Trial | |
| Australia | 570130 | ⤷ Start Trial | |
| Bulgaria | 60415 | ⤷ Start Trial | |
| Canada | 1255314 | DERIVES DE 2-(PYRID-2-YL)-METHYLTHIO(OU METHYLSULFINYL)BENZIMIDAZOLE ET LEUR PREPARATION (2-(PYRID-2-YL)-METHYLTHIO(OR METHYLSULFINYL) BENZIMIDAZOLE DERIVATIVES AND THEIR PRODUCTION) | ⤷ Start Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for PREVACID IV
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0174726 | SPC/GB94/011 | United Kingdom | ⤷ Start Trial | SPC/GB94/011, EXPIRES: 20051210 |
| 0174726 | 93C0021 | Belgium | ⤷ Start Trial | PRODUCT NAME: LANSOPRAZOLE; NAT. REG.: 150 S 539 F 4 19921119; FIRST REG.: FR 333 412.1 19901211 |
| 0328535 | 96C0021 | Belgium | ⤷ Start Trial | PRODUCT NAME: LANSOPRAZOLE + CLARITHROMYCINE + METRONIDAZOLE; REGISTRATION NO/DATE IN FRANCE: K 27 17033R DU 19960209; REGISTRATION NO/DATE AT EEC: K 27 17033R DU 19960209 |
| 1129088 | 2014/008 | Ireland | ⤷ Start Trial | PRODUCT NAME: DEXLANSOPRAZOLE OR A SALT THEREOF; NAT REGISTRATION NO/DATE: PA1864/001/001-002;PA1864/002/001-002 20131125; FIRST REGISTRATION NO/DATE: 47911 47912 47913 47914 20130919 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch